Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBRX NASDAQ:GYRE NASDAQ:OKUR NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBRXForte Biosciences$54.78-8.2%$26.19$9.10▼$62.46$828.99M2.851.02 million shs575,792 shsGYREGyre Therapeutics$5.94-1.2%$6.24$5.44▼$9.42$670.05M1.89108,378 shs33,768 shsOKUROnKure Therapeutics$4.12-2.4%$4.23$1.91▼$5.38$170.47M0.27321,615 shs186,005 shsSPRYARS Pharmaceuticals$5.94-1.0%$8.39$5.76▼$18.63$589.86M0.951.99 million shs3.48 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBRXForte Biosciences-8.24%+12.12%+195.47%+99.56%+414.85%GYREGyre Therapeutics-1.16%-1.82%-8.33%-20.16%-21.53%OKUROnKure Therapeutics-2.37%-1.90%-5.07%-14.17%+73.11%SPRYARS Pharmaceuticals-1.00%-15.14%-43.64%-28.35%-67.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBRXForte Biosciences$54.78-8.2%$26.19$9.10▼$62.46$828.99M2.851.02 million shs575,792 shsGYREGyre Therapeutics$5.94-1.2%$6.24$5.44▼$9.42$670.05M1.89108,378 shs33,768 shsOKUROnKure Therapeutics$4.12-2.4%$4.23$1.91▼$5.38$170.47M0.27321,615 shs186,005 shsSPRYARS Pharmaceuticals$5.94-1.0%$8.39$5.76▼$18.63$589.86M0.951.99 million shs3.48 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBRXForte Biosciences-8.24%+12.12%+195.47%+99.56%+414.85%GYREGyre Therapeutics-1.16%-1.82%-8.33%-20.16%-21.53%OKUROnKure Therapeutics-2.37%-1.90%-5.07%-14.17%+73.11%SPRYARS Pharmaceuticals-1.00%-15.14%-43.64%-28.35%-67.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBRXForte Biosciences 2.60Moderate Buy$68.7525.50% UpsideGYREGyre Therapeutics 2.25Hold$17.00186.20% UpsideOKUROnKure Therapeutics 2.00Hold$21.00409.71% UpsideSPRYARS Pharmaceuticals 2.50Moderate Buy$28.20374.75% UpsideCurrent Analyst Ratings BreakdownLatest OKUR, FBRX, GYRE, and SPRY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026FBRXForte Biosciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$74.007/21/2026FBRXForte Biosciences BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$74.007/20/2026OKUROnKure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.007/8/2026FBRXForte Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026GYREGyre Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/25/2026SPRYARS Pharmaceuticals Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $24.006/1/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/29/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026SPRYARS Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$12.00 ➝ $30.005/15/2026SPRYARS Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026GYREGyre Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBRXForte BiosciencesN/AN/AN/AN/A$4.71 per shareN/AGYREGyre Therapeutics$116.59M5.68$0.22 per share27.05$1.48 per share4.01OKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ASPRYARS Pharmaceuticals$98.99M5.96N/AN/A$1.16 per share5.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBRXForte Biosciences-$69.38M-$4.64N/AN/AN/AN/A-106.17%-85.50%8/13/2026 (Estimated)GYREGyre Therapeutics$5.03M-$0.09N/AN/AN/A-5.44%3.13%2.67%8/10/2026 (Estimated)OKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)SPRYARS Pharmaceuticals-$171.30M-$2.01N/AN/AN/A-200.00%-153.61%-60.85%8/12/2026 (Estimated)Latest OKUR, FBRX, GYRE, and SPRY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026FBRXForte Biosciences-$0.9248N/AN/AN/AN/AN/A8/12/2026Q2 2026SPRYARS Pharmaceuticals-$0.4766N/AN/AN/A$31.33 millionN/A8/11/2026Q2 2026OKUROnKure Therapeutics-$0.58N/AN/AN/A$0.17 millionN/A8/10/2026Q2 2026GYREGyre Therapeutics-$0.08N/AN/AN/A$26.49 millionN/A5/15/2026Q1 2026SPRYARS Pharmaceuticals-$0.53-$0.61-$0.08-$0.61$22.20 million$22.68 million5/11/2026Q1 2026FBRXForte Biosciences-$1.16-$1.24-$0.08-$1.24N/AN/A5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFBRXForte BiosciencesN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBRXForte BiosciencesN/A2.752.75GYREGyre TherapeuticsN/A4.644.06OKUROnKure TherapeuticsN/A13.7813.78SPRYARS Pharmaceuticals2.794.944.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBRXForte Biosciences77.63%GYREGyre Therapeutics23.99%OKUROnKure Therapeutics90.98%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipFBRXForte Biosciences4.40%GYREGyre Therapeutics9.50%OKUROnKure Therapeutics2.17%SPRYARS Pharmaceuticals33.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBRXForte Biosciences513.89 million13.28 millionOptionableGYREGyre Therapeutics40111.49 million100.90 millionNo DataOKUROnKure TherapeuticsN/A40.40 million39.52 millionN/ASPRYARS Pharmaceuticals9099.30 million65.74 millionOptionableOKUR, FBRX, GYRE, and SPRY HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 23 at 10:00 AM | prnewswire.comLevin Capital Strategies L.P. Has $4.44 Million Holdings in ARS Pharmaceuticals, Inc. $SPRYJuly 23 at 5:44 AM | marketbeat.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 23 at 3:15 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 21, 2026 | globenewswire.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Time to Sell?July 20, 2026 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.2% - Time to Sell?July 19, 2026 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 18, 2026 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 5.2% - Here's WhyJuly 17, 2026 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 16, 2026 | prnewswire.comARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEOJuly 15, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 14, 2026 | globenewswire.comGeneral American Investors Co. Inc. Buys 167,195 Shares of ARS Pharmaceuticals, Inc. $SPRYJuly 12, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Stevanato Group (STVN) and ARS Pharmaceuticals (SPRY)July 11, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 9, 2026 | prnewswire.comCan ARS Pharma's New CEO Unlock Neffy's Potential?July 9, 2026 | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRYJuly 7, 2026 | globenewswire.comARS Pharmaceuticals appoints Donn Casale as CEOJuly 7, 2026 | tipranks.comARS Pharmaceuticals Announces CEO SuccessionJuly 7, 2026 | globenewswire.comARS Pharmaceuticals (SPRY) Securities Fraud Investigation - Levi & KorsinskyJuly 6, 2026 | prnewswire.comSPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities FraudJuly 1, 2026 | tmcnet.comJanney Montgomery Scott LLC Has $16.19 Million Position in ARS Pharmaceuticals, Inc. $SPRYJuly 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOKUR, FBRX, GYRE, and SPRY Company DescriptionsForte Biosciences NASDAQ:FBRX$54.78 -4.92 (-8.24%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$54.40 -0.38 (-0.69%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Gyre Therapeutics NASDAQ:GYRE$5.94 -0.07 (-1.16%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.95 +0.01 (+0.17%) As of 07/24/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.OnKure Therapeutics NASDAQ:OKUR$4.12 -0.10 (-2.37%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.14 +0.01 (+0.36%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.ARS Pharmaceuticals NASDAQ:SPRY$5.94 -0.06 (-1.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$6.04 +0.11 (+1.77%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
